These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 17643935)

  • 1. Glatiramer acetate: mechanisms of action in multiple sclerosis.
    Schrempf W; Ziemssen T
    Autoimmun Rev; 2007 Aug; 6(7):469-75. PubMed ID: 17643935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glatiramer acetate: mechanisms of action in multiple sclerosis.
    Ziemssen T; Schrempf W
    Int Rev Neurobiol; 2007; 79():537-70. PubMed ID: 17531858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.
    Liblau R
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S17-23. PubMed ID: 20106343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis?
    Jee Y; Liu R; Bai XF; Campagnolo DI; Shi FD; Vollmer TL
    Int Immunol; 2006 Apr; 18(4):537-44. PubMed ID: 16481342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ.
    Aharoni R; Kayhan B; Eilam R; Sela M; Arnon R
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14157-62. PubMed ID: 14614135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies.
    Teitelbaum D; Aharoni R; Klinger E; Kreitman R; Raymond E; Malley A; Shofti R; Sela M; Arnon R
    Ann N Y Acad Sci; 2004 Dec; 1029():239-49. PubMed ID: 15681762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulation by the copolymer glatiramer acetate.
    Arnon R; Sela M
    J Mol Recognit; 2003; 16(6):412-21. PubMed ID: 14732933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy.
    Ziemssen T; Kümpfel T; Schneider H; Klinkert WE; Neuhaus O; Hohlfeld R
    J Neurol Sci; 2005 Jun; 233(1-2):109-12. PubMed ID: 15869765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of glatiramer acetate in the treatment of multiple sclerosis.
    Wolinsky JS
    Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glatiramer acetate.
    Comi G; Moiola L
    Neurologia; 2002 May; 17(5):244-58. PubMed ID: 12031214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent insights into the mechanism of action of glatiramer acetate.
    Kala M; Miravalle A; Vollmer T
    J Neuroimmunol; 2011 Jun; 235(1-2):9-17. PubMed ID: 21402415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment.
    Dressel A; Vogelgesang A; Brinkmeier H; Mäder M; Weber F
    J Neuroimmunol; 2006 Dec; 181(1-2):133-40. PubMed ID: 17084909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate.
    Jung S; Siglienti I; Grauer O; Magnus T; Scarlato G; Toyka K
    J Neuroimmunol; 2004 Mar; 148(1-2):63-73. PubMed ID: 14975587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis.
    Sanna A; Fois ML; Arru G; Huang YM; Link H; Pugliatti M; Rosati G; Sotgiu S
    Clin Exp Immunol; 2006 Feb; 143(2):357-62. PubMed ID: 16412061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients.
    Kim HJ; Biernacki K; Prat A; Antel JP; Bar-Or A
    Clin Immunol; 2004 Apr; 111(1):38-46. PubMed ID: 15093550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis.
    Jee Y; Piao WH; Liu R; Bai XF; Rhodes S; Rodebaugh R; Campagnolo DI; Shi FD; Vollmer TL
    Clin Immunol; 2007 Oct; 125(1):34-42. PubMed ID: 17632037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.
    Aharoni R
    J Autoimmun; 2014 Nov; 54():81-92. PubMed ID: 24934599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications.
    Arnon R; Aharoni R
    Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14593-8. PubMed ID: 15371592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action.
    Farina C; Weber MS; Meinl E; Wekerle H; Hohlfeld R
    Lancet Neurol; 2005 Sep; 4(9):567-75. PubMed ID: 16109363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy.
    Allie R; Hu L; Mullen KM; Dhib-Jalbut S; Calabresi PA
    Arch Neurol; 2005 Jun; 62(6):889-94. PubMed ID: 15956159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.